Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China

Autor: Wei Dai, Chunxia Zhao, Xin Li, Lingquan Kong, He Wu, Vishnu Prasad Adhikari, Guosheng Ren, Kai-nan Wu, Hongyuan Li, Linjie Lu
Rok vydání: 2017
Předmět:
Zdroj: Oncotarget
ISSN: 1949-2553
Popis: // Lin-Jie Lu 1, 2, * , Vishnu Prasad Adhikari 1, * , Chun-Xia Zhao 1, * , He Wu 1, * , Wei Dai 1, * , Xin Li 1 , Hong-Yuan Li 1 , Guo-Sheng Ren 1 , Kai-Nan Wu 1 and Ling-Quan Kong 1 1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China 2 Department of Thyroid and Breast Surgery, Liuzhou People’s Hospital, Liuzhou 545006, China * These authors have contributed equally to this work Correspondence to: Ling-Quan Kong, email: huihuikp@163.com Keywords: breast cancer, hepatitis B virus, risk factor, etiology, breast oncohepatology Received: August 27, 2016 Accepted: June 04, 2017 Published: July 10, 2017 ABSTRACT Purpose: Chronic hepatitis C virus (HCV) infection is reported to be associated with early-onset breast cancer, while, as a hepadnavirus, hepatitis B virus(HBV) infection is more common than HCV in China. In this article, it is aimed to study the relationship between HBV infection and risk of breast cancer in China. Methods: The clinical data of 2452 cases of initially diagnosed breast cancer and 1926 cases of benign breast disease (as controls) with the consecutive reports of HBV serological markers and liver function tests, available in the Electronic Medical Records of the Breast Cancer Center of Chongqing, the southwest of China, from January 2011 to March 2015, were collected for analysis. Results: The average age of the initially diagnosed breast cancer patients was 50.3±11.3 years with the age peaking about 40- 49yeaers (39.7%). The positive rate (8.2%) of hepatitis B surface antigen in breast cancer patients was relatively higher than that (7.8%) in controls ( P >0.05). While, the positive rate (66.4%)of hepatitis B core antibody in breast cancer patients was significantly higher than that (53.7%) in controls ( P
Databáze: OpenAIRE